Search
Paclitaxel Treatment Options
A collection of 2030 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1909 - 1920 of 2030
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic, recurrent, or refractory endometrial cancer.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
06/13/2012
Locations: MBCCOP - University of South Alabama, Mobile, Alabama +93 locations
Conditions: Endometrial Cancer
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined with paclitaxel or gemcitabine in treating cervical cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with paclitaxel to that of cisplatin combined with gemcitabine in treating women who have recurrent, persi... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/11/2012
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +105 locations
Conditions: Cervical Cancer
Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/06/2012
Locations: Comprehensive Cancer Institute of Huntsville, Huntsville, Alabama +30 locations
Conditions: Breast Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have stage III non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2012
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Conditions: Lung Cancer
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase I/II trial to study the effectiveness of ifosfamide, teniposide, and paclitaxel in treating patients who have relapsed non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2012
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Conditions: Lymphoma
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
Terminated
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/31/2012
Locations: GSK Investigational Site, Hot Springs, Arkansas +27 locations
Conditions: Relapsed Breast Cancer, Neoplasms, Breast
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Completed
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2012
Locations: Bay Area Cancer Research Group, Concord, California +51 locations
Conditions: Carcinoma, Non-Small-Cell Lung
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Completed
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2012
Locations: Not set, Detroit, Michigan +4 locations
Conditions: Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than on drug and combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients with advanced or metastatic cancer of the esophagus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2012
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina
Conditions: Esophageal Cancer
Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention
Unknown
The purpose of this study is to assess the safety and efficacy of administering intra-arterial paclitaxel in the femoropopliteal arteries via the TAPAS catheter following percutaneous revascularization to prevent restenosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2012
Locations: Trinity Medical Center, Bettendorf, Iowa
Conditions: Restenosis, Peripheral Arterial Disease
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Completed
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.
Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2012
Locations: Veeda Oncology, Columbus, Ohio
Conditions: Metastatic Breast Cancer
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
Terminated
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.
Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuously.
Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2012
Locations: Veeda Oncology, Columbus, Ohio
Conditions: Breast Cancer
1909 - 1920 of 2030